Light Sciences Cancer Study Advances

Xconomy Seattle — 

Light Sciences Oncology, the Bellevue, WA-based developer of a technology that combines a drug with a light-emitting diode to kill tumors, said today it has completed enrollment in a pivotal clinical trial of patients with colorectal cancer that has spread to the liver. The trial enrolled 450 patients who were randomly assigned to get talaporfin sodium (Aptocine) plus chemotherapy, or the chemotherapy alone. The study is examining whether the new drug can keep the cancer from spreading further, and help people live longer. Results are expected later this year, the company said.